Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Sipp

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Perspectives in Biology and Medicine|May 29, 2018
Challenges in the Regulation of Autologous Stem Cell Interventions in the United StatesDouglas Sipp
Journal of Cellular Biochemistry|April 15, 2009
Stem cell research in Asia: a critical viewDouglas Sipp
Stem Cell Research & Therapy|May 28, 2010
Challenges in the clinical application of induced pluripotent stem cellsDouglas Sipp
Nature Medicine|September 2, 2004
'Fast-track' drug approvals hit speed bumps in JapanDouglas Sipp
The American Journal of Bioethics : AJOB|May 13, 2010
Hope alone is not an outcome: why regulations makes sense for the global stem cell industryDouglas Sipp
Cell Stem Cell|April 7, 2015
Conditional approval: Japan lowers the bar for regenerative medicine productsDouglas Sipp
Developing World Bioethics|May 24, 2016
Cell Churches and Stem Cell Marketing in South Korea and the United StatesDouglas Sipp
NPJ Regenerative Medicine|January 6, 2018
The malignant niche: safe spaces for toxic stem cell marketingDouglas Sipp
Nature Biotechnology|June 10, 2008
Millennium ends Takeda's US shopping spreeDouglas Sipp
Cell Stem Cell|March 29, 2008
No borders, only frontiers: the Global Stem Cell Research Community and the ISSCRDouglas Sipp
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Perspectives in Biology and Medicine|May 29, 2018
Challenges in the Regulation of Autologous Stem Cell Interventions in the United StatesDouglas Sipp
Journal of Cellular Biochemistry|April 15, 2009
Stem cell research in Asia: a critical viewDouglas Sipp
Stem Cell Research & Therapy|May 28, 2010
Challenges in the clinical application of induced pluripotent stem cellsDouglas Sipp
Nature Medicine|September 2, 2004
'Fast-track' drug approvals hit speed bumps in JapanDouglas Sipp
The American Journal of Bioethics : AJOB|May 13, 2010
Hope alone is not an outcome: why regulations makes sense for the global stem cell industryDouglas Sipp
Cell Stem Cell|April 7, 2015
Conditional approval: Japan lowers the bar for regenerative medicine productsDouglas Sipp
Developing World Bioethics|May 24, 2016
Cell Churches and Stem Cell Marketing in South Korea and the United StatesDouglas Sipp
NPJ Regenerative Medicine|January 6, 2018
The malignant niche: safe spaces for toxic stem cell marketingDouglas Sipp
Nature Biotechnology|June 10, 2008
Millennium ends Takeda's US shopping spreeDouglas Sipp
Cell Stem Cell|March 29, 2008
No borders, only frontiers: the Global Stem Cell Research Community and the ISSCRDouglas Sipp
Pageof 6